TWI796353B - 丙酮酸激酶調節劑及其用途 - Google Patents

丙酮酸激酶調節劑及其用途 Download PDF

Info

Publication number
TWI796353B
TWI796353B TW107128431A TW107128431A TWI796353B TW I796353 B TWI796353 B TW I796353B TW 107128431 A TW107128431 A TW 107128431A TW 107128431 A TW107128431 A TW 107128431A TW I796353 B TWI796353 B TW I796353B
Authority
TW
Taiwan
Prior art keywords
optionally substituted
alkyl
methyl
instance
protecting group
Prior art date
Application number
TW107128431A
Other languages
English (en)
Chinese (zh)
Other versions
TW201919631A (zh
Inventor
吉爾費尼 席安茜塔
查里斯 孔
濤 劉
安尼 庫馬 佩德雅納
治華 隋
振偉 蔡
崔大為
季競競
Original Assignee
美商阿吉歐斯製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商阿吉歐斯製藥公司 filed Critical 美商阿吉歐斯製藥公司
Publication of TW201919631A publication Critical patent/TW201919631A/zh
Application granted granted Critical
Publication of TWI796353B publication Critical patent/TWI796353B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW107128431A 2017-08-15 2018-08-15 丙酮酸激酶調節劑及其用途 TWI796353B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN2017097496 2017-08-15
WOPCT/CN2017/097496 2017-08-15
US201862673533P 2018-05-18 2018-05-18
US201862673526P 2018-05-18 2018-05-18
US62/673,526 2018-05-18
US62/673,533 2018-05-18

Publications (2)

Publication Number Publication Date
TW201919631A TW201919631A (zh) 2019-06-01
TWI796353B true TWI796353B (zh) 2023-03-21

Family

ID=63524352

Family Applications (3)

Application Number Title Priority Date Filing Date
TW111135803A TWI823580B (zh) 2017-08-15 2018-08-15 用於治療血液病症之丙酮酸激酶活化劑
TW107128429A TWI790271B (zh) 2017-08-15 2018-08-15 用於治療血液病症之丙酮酸激酶活化劑
TW107128431A TWI796353B (zh) 2017-08-15 2018-08-15 丙酮酸激酶調節劑及其用途

Family Applications Before (2)

Application Number Title Priority Date Filing Date
TW111135803A TWI823580B (zh) 2017-08-15 2018-08-15 用於治療血液病症之丙酮酸激酶活化劑
TW107128429A TWI790271B (zh) 2017-08-15 2018-08-15 用於治療血液病症之丙酮酸激酶活化劑

Country Status (34)

Country Link
US (8) US11590132B2 (enExample)
EP (4) EP3668512B1 (enExample)
JP (5) JP7275107B2 (enExample)
KR (3) KR102764124B1 (enExample)
CN (3) CN111032045B (enExample)
AU (4) AU2018316588B2 (enExample)
BR (2) BR112020003254A2 (enExample)
CA (1) CA3072455A1 (enExample)
CL (1) CL2020000375A1 (enExample)
CO (2) CO2020002961A2 (enExample)
CR (1) CR20200123A (enExample)
CY (1) CY1124953T1 (enExample)
DK (2) DK3668512T3 (enExample)
EC (1) ECSP20018487A (enExample)
ES (3) ES2966825T3 (enExample)
FI (1) FI3668512T3 (enExample)
HR (2) HRP20220039T1 (enExample)
HU (2) HUE057178T2 (enExample)
IL (3) IL272599B (enExample)
LT (2) LT3668512T (enExample)
MD (1) MD3668513T2 (enExample)
MX (2) MX2020001832A (enExample)
MY (1) MY204421A (enExample)
PE (1) PE20200724A1 (enExample)
PH (1) PH12020500343B1 (enExample)
PL (2) PL3668512T3 (enExample)
PT (2) PT3668512T (enExample)
RS (2) RS62871B1 (enExample)
SG (2) SG11202001353PA (enExample)
SI (2) SI3668513T1 (enExample)
SM (2) SMT202200023T1 (enExample)
TW (3) TWI823580B (enExample)
UA (1) UA126292C2 (enExample)
WO (3) WO2019035864A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11014927B2 (en) 2017-03-20 2021-05-25 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
MX2020001832A (es) * 2017-08-15 2020-07-22 Agios Pharmaceuticals Inc Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre.
WO2019079541A1 (en) 2017-10-20 2019-04-25 The Regents Of The University Of Michigan COMPOSITIONS AND METHODS FOR TREATING OCULAR DISORDERS
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
BR112021015996A2 (pt) * 2019-02-13 2021-11-09 Agios Pharmaceuticals Inc Derivados de tieno[3,2-b]pirrol[3,2-d]piridazinona e seu uso como derivados de pkm2 para o tratamento de câncer, obesidade e distúrbios relacionados a diabetes
TWI856118B (zh) * 2019-06-26 2024-09-21 日商日產化學股份有限公司 電荷輸送性塗料
EP4031132A4 (en) 2019-09-19 2023-09-13 Forma Therapeutics, Inc. Activating pyruvate kinase r
WO2022020424A1 (en) * 2020-07-21 2022-01-27 The Regents Of The University Of Michigan Compositions and methods for activating pyruvate kinase
CN112490502B (zh) * 2020-12-04 2022-01-21 广州天赐高新材料股份有限公司 一种电解液及锂二次电池
TW202245758A (zh) 2021-02-08 2022-12-01 美商全球血液治療公司 作為丙酮酸激酶活化劑之吡咯啶-吡唑
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
US20240409542A1 (en) * 2021-09-30 2024-12-12 Sitryx Therapeutics Limited Novel compounds
EP4433057A1 (en) * 2021-11-16 2024-09-25 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions
CN116159061A (zh) * 2023-03-09 2023-05-26 上海市第十人民医院 丙酮酸激酶m2激活剂在制备预防或治疗心力衰竭的药物中的应用
CN121175238A (zh) 2023-03-28 2025-12-19 本田技研工业株式会社 信息提供方法、信息提供程序、存储介质及信息处理装置
AU2024271856A1 (en) 2023-05-15 2025-11-27 Agios Pharmaceuticals, Inc. Crystalline salts or amorphous forms of 2-((1h-pyrazol-3-yl)methyl)-6-((6-aminopyridin-2-yl)methyl)-4-methyl-4,6-dihydro -5h-thiazolo[5',4':4,5]pyrrolo[2,3-d]pyridazin-5-one
WO2025010390A1 (en) * 2023-07-05 2025-01-09 Agios Pharmaceuticals, Inc. Synthesis of pyruvate kinase activators
WO2025207563A1 (en) 2024-03-27 2025-10-02 Agios Pharmaceuticals, Inc. Use of a pk activator in the treatment of sickle cell disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012151448A1 (en) * 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in therapy

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405635A (en) 1979-06-18 1983-09-20 Merrell Dow Pharmaceuticals Inc. 4-Aroylimidazol-2-ones and their use as pharmaceuticals
US4883914A (en) 1987-08-17 1989-11-28 American Cyanamid Company Benzenesulfonyl carboxamide compounds useful as herbicidal agents
IL147757A0 (en) 1999-07-30 2002-08-14 Abbott Gmbh & Co Kg 2-pyrazolin-5-ones
MXPA02002319A (es) 1999-09-04 2002-07-30 Astrazeneca Ab Derivados 2-hidroxi-2-metil-3,3,3-trifluoropropanamida con n-fenilo susbtituido que elevan la actividad de la deshidrogenasa de piruvato.
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
FR2933983B1 (fr) * 2008-07-15 2010-08-27 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JP2011529066A (ja) * 2008-07-23 2011-12-01 バーテックス ファーマシューティカルズ インコーポレイテッド 三環式ピラゾロピリジンキナーゼ阻害剤
EP2334673A1 (en) * 2008-08-29 2011-06-22 Amgen Inc. PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF
EP2344453B1 (en) 2008-10-09 2016-12-28 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
CN102448951B (zh) * 2009-04-06 2017-05-10 安吉奥斯医药品有限公司 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法
PT2448582T (pt) 2009-06-29 2017-07-10 Agios Pharmaceuticals Inc Compostos e composições terapêuticas
US20130109672A1 (en) 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase
EA023796B1 (ru) 2010-12-06 2016-07-29 Глэксо Груп Лимитед ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
CN108451955B (zh) 2011-05-03 2022-02-01 安吉奥斯医药品有限公司 用于治疗的丙酮酸激酶活化剂
WO2012151452A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc Pyruvate kinase activators for use in therapy
EP3372230B1 (en) 2011-05-03 2020-08-12 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
WO2013012915A1 (en) * 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US20140249150A1 (en) * 2011-10-13 2014-09-04 Agios Pharmaceuticals, Inc Activators of pyruvate kinase m2 and methods of treating disease
WO2014018851A1 (en) 2012-07-26 2014-01-30 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
US9458132B2 (en) 2012-11-08 2016-10-04 Agios Pharmaceuticals, Inc Therapeutic compounds and compositions and their use as PKM2 modulators
JP2016506943A (ja) * 2013-01-30 2016-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｍｋｎｋ−１キナーゼ阻害剤としてのアミドイミダゾピリダジン類
EP2968323A4 (en) 2013-03-13 2016-12-14 Flatley Discovery Lab PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
LT3661925T (lt) 2017-07-07 2022-03-10 Inflazome Limited Naujieji sulfonamido karboksamido junginiai
CA3071150A1 (en) 2017-08-15 2019-02-21 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
SG11202001182QA (en) 2017-08-15 2020-03-30 Abbvie Inc Macrocyclic mcl-1 inhibitors and methods of use
MX2020001832A (es) 2017-08-15 2020-07-22 Agios Pharmaceuticals Inc Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre.
AR112475A1 (es) 2017-08-15 2019-10-30 Agios Pharmaceuticals Inc Moduladores de piruvato quinasas y uso de los mismos
BR112021015996A2 (pt) * 2019-02-13 2021-11-09 Agios Pharmaceuticals Inc Derivados de tieno[3,2-b]pirrol[3,2-d]piridazinona e seu uso como derivados de pkm2 para o tratamento de câncer, obesidade e distúrbios relacionados a diabetes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012151448A1 (en) * 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Clin Cancer Res; 18(20) October 15, 2012，Mayumi Tamada1 , Makoto Suematsu2,4, and Hideyuki Saya ，Pyruvate Kinase M2: Multiple Faces for Conferring Benefits on Cancer Cells
EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 28, no. 1，SEVKI ADEM ΕΤ AL: "Pyruvate kinase activators as a therapy target: a patent review 2011-2017";Clin Cancer Res; 18(20) October 15, 2012，Mayumi Tamada1 , Makoto Suematsu2,4, and Hideyuki Saya ，Pyruvate Kinase M2: Multiple Faces for Conferring Benefits on Cancer Cells *

Also Published As

Publication number Publication date
DK3668513T3 (da) 2022-01-10
CA3072455A1 (en) 2019-02-21
PL3668512T3 (pl) 2023-06-19
US20210130371A1 (en) 2021-05-06
HUE061910T2 (hu) 2023-08-28
PT3668512T (pt) 2023-05-22
MX2020001832A (es) 2020-07-22
EP3668881A1 (en) 2020-06-24
CN111032046A (zh) 2020-04-17
US11872225B2 (en) 2024-01-16
TW201919631A (zh) 2019-06-01
CN117186119A (zh) 2023-12-08
SG11202001353PA (en) 2020-03-30
AU2018316587A1 (en) 2020-02-20
IL272599A (en) 2020-03-31
CN111032045A (zh) 2020-04-17
TW202323258A (zh) 2023-06-16
JP2023027276A (ja) 2023-03-01
CN111032046B (zh) 2023-09-26
BR112020003254A2 (pt) 2020-10-27
AU2018316587B2 (en) 2023-05-11
LT3668513T (lt) 2022-03-25
JP2024147805A (ja) 2024-10-16
KR20230127364A (ko) 2023-08-31
ES2905100T3 (es) 2022-04-07
JP2020531432A (ja) 2020-11-05
IL272599B (en) 2022-08-01
HUE057178T2 (hu) 2022-04-28
US20200206225A1 (en) 2020-07-02
IL292530B2 (en) 2023-06-01
DK3668512T3 (da) 2023-05-22
HRP20220039T1 (hr) 2022-04-15
IL272597B (en) 2022-06-01
SMT202300146T1 (it) 2023-07-20
AU2018316588B2 (en) 2023-02-02
AU2018316588A1 (en) 2020-02-20
AU2023202772A1 (en) 2023-05-18
CN111032045B (zh) 2023-08-15
US11590132B2 (en) 2023-02-28
CO2020002961A2 (es) 2020-04-13
RU2020110573A (ru) 2021-09-16
BR112020003262A2 (pt) 2020-09-01
JP7301040B2 (ja) 2023-06-30
KR102642408B1 (ko) 2024-02-28
US20230226055A1 (en) 2023-07-20
WO2019035863A8 (en) 2019-03-28
US20250144093A1 (en) 2025-05-08
RS64221B1 (sr) 2023-06-30
US20220395503A1 (en) 2022-12-15
KR102764124B1 (ko) 2025-02-05
WO2019035863A1 (en) 2019-02-21
EP3668512A1 (en) 2020-06-24
PH12020500343A1 (en) 2021-02-08
CR20200123A (es) 2020-06-29
US11364240B2 (en) 2022-06-21
MY204421A (en) 2024-08-28
US20220233541A1 (en) 2022-07-28
CO2020002959A2 (es) 2020-04-13
PH12020500343B1 (en) 2024-02-21
AU2023202772B2 (en) 2024-05-16
PE20200724A1 (es) 2020-07-21
MD3668513T2 (ro) 2022-04-30
KR20200054200A (ko) 2020-05-19
LT3668512T (lt) 2023-06-12
HRP20230452T1 (hr) 2023-07-21
CY1124953T1 (el) 2023-01-05
JP2023052478A (ja) 2023-04-11
PT3668513T (pt) 2022-01-21
TWI823580B (zh) 2023-11-21
US11957680B2 (en) 2024-04-16
EP3668513B1 (en) 2021-11-10
ECSP20018487A (es) 2020-05-29
AU2024205818A1 (en) 2024-09-05
TWI790271B (zh) 2023-01-21
US20200207785A1 (en) 2020-07-02
CA3071993A1 (en) 2019-02-21
ES2966825T3 (es) 2024-04-24
CL2020000375A1 (es) 2020-12-11
SI3668513T1 (sl) 2022-04-29
WO2019035864A8 (en) 2019-03-28
IL272597A (en) 2020-03-31
JP7275107B2 (ja) 2023-05-17
RS62871B1 (sr) 2022-02-28
JP2020531443A (ja) 2020-11-05
TW201920203A (zh) 2019-06-01
SMT202200023T1 (it) 2022-03-21
SG11202001262QA (en) 2020-03-30
EP3668513A1 (en) 2020-06-24
KR102717594B1 (ko) 2024-10-14
JP7530453B2 (ja) 2024-08-07
KR20200054199A (ko) 2020-05-19
US12133853B2 (en) 2024-11-05
EP4026838A1 (en) 2022-07-13
FI3668512T3 (fi) 2023-05-12
EP3668512B1 (en) 2023-02-15
WO2019035865A8 (en) 2019-03-28
US11464775B2 (en) 2022-10-11
WO2019035864A1 (en) 2019-02-21
UA126292C2 (uk) 2022-09-14
US20210077490A1 (en) 2021-03-18
MX2020001833A (es) 2020-07-22
WO2019035865A1 (en) 2019-02-21
US11040036B2 (en) 2021-06-22
SI3668512T1 (sl) 2023-06-30
RU2020110573A3 (enExample) 2021-12-24
ES2944545T3 (es) 2023-06-22
EP3668881B1 (en) 2023-10-04
IL292530A (en) 2022-06-01
PL3668513T3 (pl) 2022-03-21

Similar Documents

Publication Publication Date Title
TWI796353B (zh) 丙酮酸激酶調節劑及其用途
RU2537945C2 (ru) Триазиновые, пиримидиновые и пиридиновые аналоги и их применение в качестве терапевтических агентов и диагностических проб
EP2763976B1 (en) 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
US20220127267A1 (en) Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders
CA2767097A1 (en) Pyrazolopyrimidine jak inhibitor compounds and methods
CN112236429A (zh) 用作ii型irak抑制剂的杂芳基化合物及其用途
JP2022510380A (ja) チロシンキナーゼ阻害剤、組成及びその方法
TW202325288A (zh) 新穎化合物
RU2797518C2 (ru) Модуляторы пируваткиназы и их применение
HK40030322B (en) Pyruvate kinase modulators and use thereof
HK40030322A (en) Pyruvate kinase modulators and use thereof
HK40077435A (en) Pyruvate kinase activators for use in treating blood disorders
HK40043591A (en) Heteroaryl compounds as type ii irak inhibitors and uses thereof
HK40030323B (en) Pyruvate kinase activators for use in treating blood disorders
HK1242303A1 (en) Heteroaryl compounds as irak inhibitors and uses thereof